Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into treatment approaches for polycythemia vera (PV), highlighting various options for low-risk and high-risk patients. Dr Masarova also comments on novel agents that are being explored, including ruxolitinib, rusfertide, and ropeginterferon alfa-2b. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
